This article was originally published in The Gray Sheet
Zoll's LifeVest wearable cardioverter defibrillator line-up expands to include Life-Padz WCD 3000S system. Approved via PMA supplement in May, the Lifecor-manufactured device is distributed by Zoll under an exclusive April agreement covering Lifecor technology for in-hospital use. Based on the initial LifeVest, approved in 2001, the next-generation Life-Padz uses three shock delivery pads instead of a full vest to facilitate short-term use and "unhindered mobility" in the hospital, Zoll explains. The device lists for $17,000...
You may also be interested in...
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.